专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP3101131A1 ANTI-TRANSTHYRETIN HUMANIZED ANTIBODY 有权转让
标题翻译：人类抗逆转录酶抗体
公开(公告)号：EP3101131A1
公开(公告)日：2016-12-07
申请号：EP15743230.3
申请日：2015-01-23
申请人： The Chemo-Sero-Therapeutic Research Institute , National University Corporation Kumamoto University
发明人： HOSOI, Akihiko , TORIKAI, Masaharu , TAKEO, Tomoyo , UENO, Masayo , HIGUCHI, Hirofumi , SOEJIMA, Kenji , NAKASHIMA, Toshihiro , ANDO, Yukio , JONO, Hirofumi , SU, Yu
IPC分类号： C12N15/09 , A61K39/395 , A61P25/28 , C07K16/18 , C12M1/34 , C12N15/02 , C12P21/08 , G01N33/53
摘要： A humanized antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The humanized antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a humanized antibody suitable for application to human body.
摘要翻译：包含由SEQ ID NO：1〜3所示的氨基酸序列构成的H链的互补决定区和由SEQ ID NOs所示的氨基酸序列构成的L链的互补决定区的人源化抗体：4〜6。本发明的人源化抗体具有特异性结合具有结构变化的转甲状腺素蛋白（TTR）的活性和抑制TTR原纤维化的活性，并且是适用于人体的人源化抗体。

2. 发明授权

EP1405912B1 GENETICALLY MODIFIED ECARIN AND PROCESS FOR PRODUCING THE SAME 有权
标题翻译：基因改造蝰蛇毒和方法及其
公开(公告)号：EP1405912B1
公开(公告)日：2012-09-05
申请号：EP02745822.3
申请日：2002-07-04
申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
发明人： YONEMURA, Hiroshi , IMAMURA, Takayuki , NAKATAKE, Hiroshi , SOEJIMA, Kenji , NOZAKI, Chikateru
IPC分类号： C12P21/02
CPC分类号： C12N9/6418

3. 发明公开

EP2172544A1 NOVEL ADAMTS-13 MUTANT 有权
标题翻译：新的ADAMTS-13突变体
公开(公告)号：EP2172544A1
公开(公告)日：2010-04-07
申请号：EP08777372.7
申请日：2008-06-19
申请人： Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
发明人： SOEJIMA, Kenji
IPC分类号： C12N9/64 , A61K38/00 , A61P7/02 , A61P43/00 , C12N15/09
CPC分类号： C12N9/6489 , A61K38/00 , A61K38/4886 , C12Y304/24087
摘要： The present invention provides a method of enhancing an enzymatic activity of ADAMTS-13 and/or a method of reducing reactivity to an anti-ADAMTS-13 neutralizing antibody as well as a mutant of ADAMTS-13 prepared by the methods. The method of the present invention is characterized by substituting at least one charged amino acid in a disintegrin-like domain, a cysteine-rich domain or a spacer domain of ADAMTS-13 other than the following amino acids with a different amino acid: arginine at position 326, aspartic acid at position 330, aspartic acid at position 343 and arginine at position 349 in the disintegrin-like domain, aspartic acid at position 480, arginine at position 488, arginine at position 498, arginine at position 507, aspartic acid at position 533 and aspartic acid at position 543 in the cysteine-rich domain, and glutamic acid at position 641 and arginine at position 660 in the spacer domain. The present invention also provides a therapeutic agent for thrombotic disease comprising as an active ingredient the mutant of ADAMTS-13 prepared by the method.
摘要翻译：本发明提供了增强ADAMTS-13的酶活性的方法和/或降低对抗ADAMTS-13中和抗体的反应性的方法以及通过所述方法制备的ADAMTS-13的突变体。本发明的方法的特征在于用不同于下列氨基酸的ADAMTS-13的解聚素样结构域，富半胱氨酸结构域或间隔区中的至少一个带电氨基酸替换为不同的氨基酸：精氨酸第326位，第330位天冬氨酸，第343位天冬氨酸和第349位精氨酸，第480位天冬氨酸，第488位精氨酸，第498位精氨酸，第507位精氨酸，第507位天冬氨酸 533位和天冬氨酸位于富含半胱氨酸结构域的543位，谷氨酸位于位置区641位，精氨酸位于660位。本发明还提供了一种用于血栓性疾病的治疗剂，其包含通过该方法制备的ADAMTS-13突变体作为活性成分。

4. 发明公开

EP1405910A1 PROCESS FOR PRODUCING HUMAN THROMBIN BY GENE MODIFICATION TECHNIQUE 有权
标题翻译： VERFAHREN ZUR HERSTELLLUNG VON MENSCHLICHEM THROMBIN MITTELS GENMODIFIKATIONSTECHNIK
公开(公告)号：EP1405910A1
公开(公告)日：2004-04-07
申请号：EP02743820.9
申请日：2002-07-04
申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute
发明人： YONEMURA, Hiroshi , IMAMURA, Takayuki , NAKATAKE, Hiroshi , SOEJIMA, Kenji , NOZAKI, Chikateru
IPC分类号： C12N15/09 , C12P21/02
CPC分类号： C12N9/6424 , C12Y304/21005
摘要： A genetic recombinant human thrombin is provided. Human thrombin is efficiently prepared by the genetic engineering technique comprising the steps: (1) culturing a transfectant animal cell transfected with an expression vector in which a gene encoding human prethrombin is incorporated to the downstream of a promoter so as to produce and accumulate prethrombin in culture supernatant and recovering the produced human prethrombin; (2) treating a solution containing human prethrombin recovered in step (1) with ecarin so as to convert human prethrombin into human thrombin; and (3) purifying the solution obtained after the above activation process to obtain purified human thrombin. The present invention allows for provision of human thrombin in a large scale in a safe and economical manner due to exclusion of blood-derived components.
摘要翻译：使用包含培养转化体的基因修饰技术生产人凝血酶，通过用艾卡林处理活化后将回收的人凝血酶原转化为人凝血酶，并从反应混合物中纯化人凝血酶是新的。使用基因修饰技术生产人凝血酶包括：（a）培养通过将携带编码凝血酶原基因的基因的表达载体转化到动物细胞构建的转化体，所述基因整合到启动子的下游，并将如此产生的凝血酶原聚集在细胞中收集培养基（b）通过用艾卡林处理活化后将回收的人凝血酶原转化为人凝血酶; 和（c）从反应混合物中纯化此类人凝血酶。活动：止血。没有给出生物数据。行动机制：无给予。

5. 发明授权

EP2172544B1 NOVEL ADAMTS-13 MUTANT 有权
标题翻译：新ADAMTS-13突变体
公开(公告)号：EP2172544B1
公开(公告)日：2014-11-12
申请号：EP08777372.7
申请日：2008-06-19
申请人： The Chemo-Sero-Therapeutic Research Institute
发明人： SOEJIMA, Kenji
IPC分类号： C12N9/64 , A61K38/00 , A61P7/02 , A61P43/00 , C12N15/09
CPC分类号： C12N9/6489 , A61K38/00 , A61K38/4886 , C12Y304/24087

6. 发明授权

EP2202306B1 RECOMBINANT FACTOR X WITH NO GLYCOSYLATION AND METHOD FOR PREPARING THE SAME 有权
标题翻译：重组凝血因子X无其制备糖基化和方法
公开(公告)号：EP2202306B1
公开(公告)日：2012-12-19
申请号：EP08837781.7
申请日：2008-10-08
申请人： The Chemo-Sero-Therapeutic Research Institute
发明人： SOEJIMA, Kenji , IMAMURA, Takayuki , KAWAMURA, Ryoichi , NAKATAKE, Hiroshi , MAEYASHIKI, Arisa , TOGO, Hitomi
IPC分类号： C12N9/64
CPC分类号： C12N9/6432 , A61K38/00 , C12Y304/21006

7. 发明授权

EP1405912B8 GENETICALLY MODIFIED ECARIN AND PROCESS FOR PRODUCING THE SAME 有权
标题翻译：经遗传修饰的EC AND及其生产方法
公开(公告)号：EP1405912B8
公开(公告)日：2012-10-24
申请号：EP02745822.3
申请日：2002-07-04
申请人： The Chemo-Sero-Therapeutic Research Institute
发明人： YONEMURA, Hiroshi , IMAMURA, Takayuki , NAKATAKE, Hiroshi , SOEJIMA, Kenji , NOZAKI, Chikateru
IPC分类号： C12P21/02
CPC分类号： C12N9/6418

8. 发明公开

EP1405912A1 GENETICALLY MODIFIED ECARIN AND PROCESS FOR PRODUCING THE SAME 有权
标题翻译：遗传改良剂VERFAHREN ZU DESSEN HERSTELLUNG
公开(公告)号：EP1405912A1
公开(公告)日：2004-04-07
申请号：EP02745822.3
申请日：2002-07-04
申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute
发明人： YONEMURA, Hiroshi , IMAMURA, Takayuki , NAKATAKE, Hiroshi , SOEJIMA, Kenji , NOZAKI, Chikateru
IPC分类号： C12N15/12 , C07K14/435 , C12P21/02
CPC分类号： C12N9/6418
摘要： A recombinant ecarin protein that specifically activates prothrombin, said protein being efficiently prepared by the genetic engineering technique comprising the steps: (1) culturing a transformant microorganism or animal cell transformed with an expression vector in which a gene encoding ecarin is incorporated to the downstream of a promoter so as to produce and accumulate ecarin in culture supernatant or within said transformant and recovering the produced ecarin; and (2) purifying a solution containing the recovered ecarin to obtain purified ecarin. The present invention allows for production of recombinant ecarin on an industrial scale.
摘要翻译：用于介导Arg-Ile位点上的凝血酶原-2切割以得到α-凝血酶或用于介导凝血酶原转化的中枢蛋白酶的遗传修饰的ecarin是新的。还包括用于生产重组ecarin的独立权利要求，其包括：（a）培养通过转化微生物或动物细胞而构建的转化体，所述转化体携带携带启动子下游整合的ecarin的基因的表达载体，并收集所产生和累积的ecarin 在培养基或转化体中; 和（b）回收ecarin进行纯化。活动：止血。机制：内肽酶。

9. 发明公开

EP1055429A1 NOVEL PREVENTIVES/REMEDIES FOR IMMUNOPATHY 审中-公开
标题翻译： NEUE VORBEUGUNGSMEDIZIN / HEILMITTELFÜRIMMUNOPATHIEN
公开(公告)号：EP1055429A1
公开(公告)日：2000-11-29
申请号：EP99902905.1
申请日：1999-02-15
申请人： Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute , KOWA COMPANY LTD.
发明人： SASAKI, Takumi , KIMACHI, Kazuhiko , SOEJIMA, Kenji , KIMURA, Yumi , NOZAKI, Chikateru , FUJIYAMA, Yoshihide
IPC分类号： A61K39/09 , A61K38/16
CPC分类号： C07K14/31 , A61K38/164 , A61K39/085
摘要： A prophylactic/remedy for immunopathy for immunopathy comprising, as an active ingredient, modifications of Staphylococcal enterotoxin B (SEB) with substitution of at least one amino acid residues within the amino acid sequence of natural type SEB, or derivatives thereof, wherein said SEB modifications or derivatives thereof have inhibitory activity on T cell activation wherein they interact with specific Vβ component of T cell receptor (TCR) but are reduced in their immunological responsiveness to SEB without inducing elimination of T cells having specific Vβ component, the elimination being normally induced by natural type SEB or recombinant wild-type SEB.
摘要翻译：作为免疫疾病免疫病的预防/治疗方法，其包含用天然型SEB的氨基酸序列中的至少一个氨基酸残基取代的葡萄球菌肠毒素B（SEB）或其衍生物作为活性成分的修饰，其中所述SEB修饰或其衍生物对T细胞活化具有抑制活性，其中它们与T细胞受体（TCR）的特异性Vβ组分相互作用，但其对SEB的免疫应答降低，而不诱导具有特异性Vβ组分的T细胞的消除，消除正常由天然型SEB或重组野生型SEB诱导。

10. 发明公开

EP3101132A1 ANTI-TRANSTHYRETIN HUMAN ANTIBODY 有权转让
标题翻译：抗人甲状腺素抗体
公开(公告)号：EP3101132A1
公开(公告)日：2016-12-07
申请号：EP15743541.3
申请日：2015-01-23
申请人： The Chemo-Sero-Therapeutic Research Institute
发明人： TORIKAI, Masaharu , HOSOI, Akihiko , TAKEO, Tomoyo , UENO, Masayo , SOEJIMA, Kenji , NAKASHIMA, Toshihiro , ANDO, Yukio , JONO, Hirofumi , SU, Yu , MIZUGUCHI, Mineyuki
IPC分类号： C12N15/09 , A61K39/395 , A61P25/28 , C07K16/18 , C12M1/34 , C12N15/02 , C12P21/08 , G01N33/53
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/569 , C07K2317/76 , G01N33/6896 , G01N2800/7047
摘要： A human antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3 and a complementarity determining region of an L chain consisting of the amino acid sequence as shown in SEQ ID NOs: 4 to 6. The human antibody of the present invention has the activity to specifically bind to transthyretin (TTR) with structural change and the activity to inhibit fibrillization of TTR and is a human antibody suitable for application to human body.
摘要翻译：包含由序列号1〜3所示的氨基酸序列组成的H链的互补决定区和由序列号1所示的氨基酸序列组成的L链的互补决定区的人抗体：4至6.本发明的人抗体具有与具有结构改变的转甲状腺素蛋白（TTR）特异性结合的活性和抑制TTR原纤维化的活性，并且是适用于人体的人抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式